Search
From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections
CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in key geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028. Coverage brought to you by
Sep 28
Pareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today
CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus,...
Sep 16, 2025
Basilea, a profitable anti-infectives company, today landed a contract with BARDA worth up to $268M to develop antifungals and antibiotics
CEO David Veitch describes the news and expands on the success of Basilea's business model.
Sep 19, 2024
.png){kind=logo}